Data as of 3:59pm ET
| +0.03 / +0.67%|
The 2 analysts offering 12-month price forecasts for Amicus Therapeutics Inc have a median target of 5.50, with a high estimate of 6.00 and a low estimate of 5.00. The median estimate represents a +22.77% increase from the last price of 4.48.
The current consensus among 4 polled investment analysts is to Buy stock in Amicus Therapeutics Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.